Immunohistochemical profiles of brain metastases from breast cancer

The aim of present study is to explore the immunohistochemical profiles of brain metastases from breast cancer. We retrospectively performed immunohistochemical staining for estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor type 2 (HER2/neu), and cytokeratin...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 2008-11, Vol.90 (2), p.223-228
Main Authors: Yonemori, Kan, Tsuta, Koji, Shimizu, Chikako, Hatanaka, Yutaka, Hashizume, Kaoru, Ono, Makiko, Nakanishi, Yukihiro, Hasegawa, Tadashi, Miyakita, Yasuji, Narita, Yoshitaka, Shibui, Soichiro, Fujiwara, Yasuhiro
Format: Article
Language:English
Subjects:
Adult
Aged
Brain - metabolism
Brain - pathology
Brain Neoplasms - metabolism
Brain Neoplasms - secondary
Breast cancer
Breast Neoplasms - pathology
Chi-Square Distribution
Clinical Study - Patient Study
Epidermal Growth Factor - metabolism
Female
Gene Expression Regulation, Neoplastic
Humans
Keratins - metabolism
Medicine
Medicine & Public Health
Middle Aged
Neurology
Oncology
Receptors, Estrogen - metabolism
Receptors, Progesterone - metabolism
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of present study is to explore the immunohistochemical profiles of brain metastases from breast cancer. We retrospectively performed immunohistochemical staining for estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor type 2 (HER2/neu), and cytokeratin (CK) 5/6 in 29 patients with resected tumor specimens of brain metastases. Immunohistochemical staining for ER, PgR and HER2/neu was performed in 24 patients with primary tumors. The positive frequency of immunohistochemical profiles of ER, PgR, HER2/neu, and CK5/6, in the brain metastases were 13.8%, 6.9%, 37.9%, and 24.1%, respectively. The immunohistochemical profiles including ER, PgR, and HER2/neu of the primary tumor and the brain metastasis differed in seven patients (29.2%, N = 7/24). Interestingly, the biological characteristics of brain metastasis sometimes changed which were represented by immunohistochemical staining. Therefore, the changes in the biological features of breast cancer should be taken into account when developing treatment strategies, including new molecular-targeted drugs, for brain metastases.
ISSN:0167-594X
1573-7373
DOI:10.1007/s11060-008-9654-x